Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial

• Hoofdauteurs: Yan-Fei Wu (Auteur), Ming-Wei Wei (Auteur), Rui-Jie Wang (Auteur), Xi-Ling Guo (Auteur), Hong-Xing Pan (Auteur), Ya-Chun Gao (Auteur), Xiao-Long Li (Auteur), Xue Wang (Auteur), Xiao-Min Ma (Auteur), Peng Wan (Auteur), Li Zhou (Auteur), Ya-Wen Zhu (Auteur), Jing-Xin Li (Auteur), Feng-Cai Zhu (Auteur)
• Formaat: Boek
• Gepubliceerd in: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Background The certification of immunogenicity consistency at different production scales is indispensable for the quality control of vaccines. Research design and methods A randomized, double-blind immunobridging trial in healthy adults aged 18-59 was divided into Scale A (50 L and 800 L) and Scale...